Edition:
United States

People: G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

41.35USD
16 Nov 2018
Change (% chg)

$-0.46 (-1.10%)
Prev Close
$41.81
Open
$41.40
Day's High
$42.35
Day's Low
$40.90
Volume
104,427
Avg. Vol
118,760
52-wk High
$69.23
52-wk Low
$18.45

Eshelman, Fredric 

Dr. Fredric N. Eshelman, Pharm.D., is an Independent Director of G1 Therapeutics Inc. Dr. Eshelman has served as a member of our board of directors since February 2015. Dr. Eshelman founded Eshelman Ventures, LLC in March 2014, which invests in a variety of companies, primarily in the healthcare sector, and has served as a principal since its founding. Dr. Eshelman has served as the Chairman of the board of directors of The Medicines Company, a publicly traded biopharmaceutical company, since 2015 and has been a member of the board of Valeant Pharmaceuticals International, Inc. since 2016. Dr. Eshelman previously served on the board of directors of Furiex Pharmaceuticals, a publicly traded biopharmaceutical company, from 2010 until July 2014, when it was sold to Forest Labs/Actavis, and of Pharmaceutical Product Development, Inc., a contract research organization that was publicly traded until 2011, from 1986 until 2011. Dr. Eshelman also served as Chief Executive Officer for Pharmaceutical Product Development, Inc., a biopharmaceutical company, from June 1990 to December 2011, as Senior Vice President, Development and a member of the board of directors of the former Glaxo Inc., a pharmaceutical company, from 1989 to 1990. He also serves on the boards of directors of a number of privately held biopharmaceutical companies. Dr. Eshelman also served on the executive committee of the Medical Foundation of North Carolina, the board of the North Carolina Biotechnology Center, and the Board of Trustees for the University of North Carolina—Wilmington. In addition, Dr. Eshelman serves as an adjunct professor at the University of North Carolina—Chapel Hill School of Pharmacy, where he chairs the Board of Visitors. Dr. Eshelman received his B.S. in pharmacy from the University of North Carolina—Chapel Hill, and a Pharm.D. from the University of Cincinnati.

Basic Compensation

Total Annual Compensation, USD 229,031
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 229,031

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Seth Rudnick

257,523

Mark Velleca

738,217

Barclay Phillips

3,346,580

Rajesh Malik

688,715

Terry Murdock

1,152,080

Jay Strum

--
As Of  30 Dec 2017